- cafead Aug 30, 2021 at 11:22: AM
via Rivals are closing in on Sanofi and Regeneron’s Dupixent. With AbbVie’s Rinvoq having already bested Dupixent in atopic dermatitis, Pfizer has now chalked up its own efficacy win over the blockbuster incumbent without sharing key details of safety data that could shape the category.
Earlier work has already pointed to the potential for Pfizer’s JAK1 inhibitor abrocitinib to outperform Dupixent. The latest phase 3b data confirm the advantages of abrocitinib while leaving unanswered questions about whether Pfizer has the complete package of attributes needed to make a big dent in sales of Dupixent.
article source
Earlier work has already pointed to the potential for Pfizer’s JAK1 inhibitor abrocitinib to outperform Dupixent. The latest phase 3b data confirm the advantages of abrocitinib while leaving unanswered questions about whether Pfizer has the complete package of attributes needed to make a big dent in sales of Dupixent.
article source